Bain Capital Life Sciences has announced the closing of its fourth fund, securing approximately $3 billion in total commitments.
The fund includes around $2.5 billion from existing and new investors, while Bain Capital partners, employees, and affiliates contributed the remaining amount, continuing the firm’s tradition of being the largest investor in its funds.
The new fund aims to leverage the group’s investment experience to support medicines, medical devices, diagnostics, and life sciences tools targeting unmet medical needs globally.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze